| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 104 | 2025 | 473 | 15.000 |
Why?
|
| Influenza, Human | 113 | 2025 | 649 | 14.710 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 42 | 2024 | 178 | 7.040 |
Why?
|
| Vaccination | 85 | 2025 | 947 | 5.460 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 48 | 2024 | 118 | 4.190 |
Why?
|
| Seasons | 51 | 2025 | 307 | 3.490 |
Why?
|
| Hospitalization | 58 | 2025 | 1728 | 3.330 |
Why?
|
| Health Personnel | 13 | 2022 | 497 | 2.540 |
Why?
|
| Influenza B virus | 29 | 2024 | 87 | 2.310 |
Why?
|
| United States | 104 | 2025 | 10645 | 1.920 |
Why?
|
| Vaccines, Inactivated | 23 | 2024 | 144 | 1.890 |
Why?
|
| Adult | 127 | 2025 | 29018 | 1.680 |
Why?
|
| Antibodies, Viral | 17 | 2024 | 1138 | 1.670 |
Why?
|
| Emergency Responders | 5 | 2022 | 18 | 1.520 |
Why?
|
| Outpatients | 17 | 2024 | 253 | 1.420 |
Why?
|
| Respiratory Tract Infections | 10 | 2023 | 263 | 1.360 |
Why?
|
| Adolescent | 90 | 2025 | 19104 | 1.340 |
Why?
|
| Humans | 202 | 2025 | 123092 | 1.220 |
Why?
|
| Influenza A virus | 12 | 2024 | 135 | 1.200 |
Why?
|
| Young Adult | 57 | 2025 | 8839 | 1.090 |
Why?
|
| Middle Aged | 82 | 2025 | 25993 | 1.070 |
Why?
|
| Aged | 76 | 2025 | 19092 | 1.060 |
Why?
|
| Vaccines, Synthetic | 17 | 2024 | 312 | 1.040 |
Why?
|
| Vaccines, Combined | 12 | 2024 | 39 | 1.030 |
Why?
|
| Viral Load | 4 | 2023 | 381 | 0.990 |
Why?
|
| Case-Control Studies | 28 | 2025 | 3240 | 0.990 |
Why?
|
| Population Surveillance | 14 | 2022 | 383 | 0.970 |
Why?
|
| Child, Preschool | 61 | 2025 | 13884 | 0.900 |
Why?
|
| Vaccine Potency | 6 | 2020 | 9 | 0.860 |
Why?
|
| Prospective Studies | 25 | 2025 | 6027 | 0.850 |
Why?
|
| Smallpox Vaccine | 1 | 2023 | 36 | 0.830 |
Why?
|
| Ambulatory Care | 11 | 2024 | 377 | 0.810 |
Why?
|
| Male | 94 | 2025 | 60091 | 0.800 |
Why?
|
| Female | 97 | 2025 | 65538 | 0.780 |
Why?
|
| Antibody Formation | 5 | 2024 | 256 | 0.760 |
Why?
|
| Child | 68 | 2025 | 24231 | 0.740 |
Why?
|
| Occupations | 1 | 2021 | 21 | 0.740 |
Why?
|
| Hemagglutination Inhibition Tests | 6 | 2024 | 113 | 0.730 |
Why?
|
| Occupational Diseases | 1 | 2021 | 74 | 0.700 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 184 | 0.690 |
Why?
|
| Infant | 45 | 2025 | 12357 | 0.650 |
Why?
|
| Pneumonia | 1 | 2022 | 324 | 0.620 |
Why?
|
| Immunocompromised Host | 5 | 2024 | 295 | 0.600 |
Why?
|
| RNA, Messenger | 18 | 2024 | 2809 | 0.590 |
Why?
|
| Vaccines, Attenuated | 12 | 2018 | 173 | 0.560 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 105 | 0.520 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 334 | 0.520 |
Why?
|
| Dementia | 1 | 2020 | 448 | 0.500 |
Why?
|
| Immunization, Secondary | 5 | 2022 | 105 | 0.500 |
Why?
|
| Social Class | 2 | 2013 | 191 | 0.490 |
Why?
|
| Emergency Service, Hospital | 12 | 2024 | 1071 | 0.480 |
Why?
|
| Pandemics | 5 | 2023 | 1100 | 0.420 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 6369 | 0.420 |
Why?
|
| Cohort Studies | 12 | 2025 | 4703 | 0.420 |
Why?
|
| Cell Culture Techniques | 3 | 2024 | 287 | 0.410 |
Why?
|
| Asthma | 3 | 2008 | 742 | 0.410 |
Why?
|
| Disease Outbreaks | 4 | 2014 | 320 | 0.370 |
Why?
|
| Hospital Mortality | 7 | 2024 | 1009 | 0.370 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 641 | 0.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 204 | 0.360 |
Why?
|
| Orthomyxoviridae | 4 | 2014 | 50 | 0.360 |
Why?
|
| Health Status Disparities | 1 | 2013 | 218 | 0.360 |
Why?
|
| Fever | 1 | 2013 | 296 | 0.360 |
Why?
|
| Critical Illness | 2 | 2023 | 591 | 0.310 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 96 | 0.310 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 607 | 0.300 |
Why?
|
| Antiviral Agents | 4 | 2022 | 747 | 0.300 |
Why?
|
| Patient Acuity | 3 | 2025 | 63 | 0.300 |
Why?
|
| Retropharyngeal Abscess | 2 | 1996 | 7 | 0.260 |
Why?
|
| Administration, Intranasal | 7 | 2010 | 130 | 0.260 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 510 | 0.250 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 455 | 0.240 |
Why?
|
| Sentinel Surveillance | 2 | 2024 | 19 | 0.230 |
Why?
|
| Bias | 1 | 2024 | 124 | 0.230 |
Why?
|
| Presenteeism | 2 | 2023 | 2 | 0.230 |
Why?
|
| Treatment Outcome | 14 | 2025 | 12119 | 0.230 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 10 | 0.220 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 75 | 0.220 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 148 | 0.220 |
Why?
|
| Drug Utilization | 2 | 2015 | 158 | 0.220 |
Why?
|
| Acute Disease | 5 | 2018 | 1093 | 0.210 |
Why?
|
| Fluorocarbons | 1 | 2023 | 56 | 0.210 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 68 | 0.210 |
Why?
|
| Self Report | 4 | 2023 | 509 | 0.210 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 161 | 0.200 |
Why?
|
| RNA, Viral | 5 | 2023 | 540 | 0.200 |
Why?
|
| Computer Simulation | 1 | 2025 | 630 | 0.200 |
Why?
|
| Intention | 1 | 2022 | 91 | 0.190 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2001 | 40 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2018 | 1292 | 0.190 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 769 | 0.190 |
Why?
|
| Firefighters | 1 | 2022 | 31 | 0.190 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 18 | 0.190 |
Why?
|
| Age Factors | 8 | 2020 | 2803 | 0.190 |
Why?
|
| Reminder Systems | 1 | 2001 | 60 | 0.190 |
Why?
|
| Carrier State | 1 | 2021 | 76 | 0.180 |
Why?
|
| Vaccination Coverage | 4 | 2023 | 32 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2025 | 363 | 0.180 |
Why?
|
| Coinfection | 1 | 2022 | 171 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2022 | 162 | 0.170 |
Why?
|
| Viral Vaccines | 1 | 2023 | 325 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 5 | 0.170 |
Why?
|
| Hospitals | 4 | 2024 | 396 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 2846 | 0.170 |
Why?
|
| Antigenic Variation | 1 | 2020 | 39 | 0.170 |
Why?
|
| Mycobacterium marinum | 1 | 1999 | 1 | 0.170 |
Why?
|
| Oregon | 3 | 2014 | 9 | 0.160 |
Why?
|
| Cheek | 1 | 1999 | 23 | 0.160 |
Why?
|
| Immunity, Herd | 4 | 2024 | 12 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1999 | 46 | 0.160 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 217 | 0.160 |
Why?
|
| Vaccines | 1 | 2024 | 370 | 0.160 |
Why?
|
| Specimen Handling | 2 | 2022 | 140 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2024 | 1549 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 41 | 0.150 |
Why?
|
| Abscess | 1 | 1999 | 138 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 444 | 0.150 |
Why?
|
| Enterococcus faecalis | 1 | 1997 | 43 | 0.140 |
Why?
|
| Antibody Specificity | 2 | 2013 | 202 | 0.140 |
Why?
|
| Immunization Schedule | 3 | 2022 | 101 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 74 | 0.140 |
Why?
|
| Laboratories | 3 | 2021 | 83 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2024 | 821 | 0.140 |
Why?
|
| Office Visits | 2 | 2015 | 76 | 0.130 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2013 | 20 | 0.130 |
Why?
|
| Texas | 6 | 2013 | 3562 | 0.130 |
Why?
|
| Washington | 2 | 2013 | 33 | 0.130 |
Why?
|
| Accidents, Home | 1 | 1996 | 9 | 0.130 |
Why?
|
| Foot Injuries | 1 | 1996 | 7 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 591 | 0.130 |
Why?
|
| Mediastinal Emphysema | 1 | 1996 | 12 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 1996 | 18 | 0.130 |
Why?
|
| Medication Errors | 1 | 2018 | 184 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 242 | 0.130 |
Why?
|
| Incidence | 5 | 2022 | 3043 | 0.130 |
Why?
|
| Immunization | 3 | 2023 | 308 | 0.130 |
Why?
|
| Antibodies, Bacterial | 1 | 1997 | 382 | 0.130 |
Why?
|
| Efficiency | 1 | 2015 | 58 | 0.120 |
Why?
|
| Time Factors | 5 | 2025 | 6222 | 0.120 |
Why?
|
| Neutrophils | 1 | 1997 | 373 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 3665 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2392 | 0.120 |
Why?
|
| Immunity, Humoral | 2 | 2024 | 69 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 1996 | 204 | 0.110 |
Why?
|
| Asymptomatic Infections | 2 | 2024 | 33 | 0.110 |
Why?
|
| Risk Factors | 6 | 2025 | 10013 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 1996 | 241 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 1996 | 334 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1797 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 244 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 713 | 0.100 |
Why?
|
| Schools | 1 | 2014 | 221 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 714 | 0.100 |
Why?
|
| Hepatitis A Antibodies | 1 | 2011 | 9 | 0.100 |
Why?
|
| Hepatitis A Vaccines | 1 | 2011 | 10 | 0.100 |
Why?
|
| Chickenpox Vaccine | 1 | 2011 | 13 | 0.100 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2011 | 13 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2020 | 1244 | 0.100 |
Why?
|
| Health Status | 1 | 2013 | 374 | 0.090 |
Why?
|
| History, 21st Century | 3 | 2017 | 269 | 0.090 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2024 | 59 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 277 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2127 | 0.090 |
Why?
|
| Oxygen | 2 | 2023 | 547 | 0.080 |
Why?
|
| Reference Standards | 2 | 2021 | 239 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 420 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1477 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1260 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 570 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 459 | 0.080 |
Why?
|
| Nose | 2 | 2020 | 92 | 0.080 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 69 | 0.070 |
Why?
|
| Oropharynx | 2 | 2020 | 33 | 0.070 |
Why?
|
| Comorbidity | 2 | 2019 | 1495 | 0.070 |
Why?
|
| Parents | 2 | 2024 | 1031 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2022 | 1162 | 0.060 |
Why?
|
| Drainage | 2 | 1996 | 257 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 745 | 0.060 |
Why?
|
| Propensity Score | 1 | 2025 | 211 | 0.060 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 145 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 148 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 46 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2022 | 26 | 0.050 |
Why?
|
| Dyspnea | 1 | 2024 | 147 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 240 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 216 | 0.050 |
Why?
|
| Police | 1 | 2022 | 9 | 0.050 |
Why?
|
| Perception | 1 | 2024 | 220 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 3316 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 22 | 0.050 |
Why?
|
| Epitopes | 1 | 2024 | 429 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 25 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 370 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 33 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 238 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 113 | 0.050 |
Why?
|
| Nasopharynx | 2 | 2013 | 80 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 120 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 218 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 73 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 480 | 0.050 |
Why?
|
| Sample Size | 1 | 2021 | 84 | 0.050 |
Why?
|
| Absenteeism | 2 | 2014 | 19 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1309 | 0.050 |
Why?
|
| Demography | 1 | 2021 | 239 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 281 | 0.050 |
Why?
|
| Research Design | 1 | 2025 | 682 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 209 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 1877 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2015 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1115 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 69 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 16037 | 0.040 |
Why?
|
| Pharyngitis | 1 | 2018 | 31 | 0.040 |
Why?
|
| School Health Services | 2 | 2010 | 101 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 37 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 368 | 0.040 |
Why?
|
| Blood Bactericidal Activity | 1 | 1997 | 17 | 0.040 |
Why?
|
| Opsonin Proteins | 1 | 1997 | 22 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 190 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 826 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 483 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 179 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1997 | 58 | 0.040 |
Why?
|
| Frailty | 1 | 2019 | 98 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 464 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1084 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2017 | 63 | 0.040 |
Why?
|
| Pharynx | 1 | 2017 | 64 | 0.030 |
Why?
|
| Sinusitis | 1 | 2018 | 117 | 0.030 |
Why?
|
| Phagocytosis | 1 | 1997 | 169 | 0.030 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 83 | 0.030 |
Why?
|
| Prevalence | 1 | 2023 | 2404 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2016 | 22 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1682 | 0.030 |
Why?
|
| Pregnancy | 2 | 2022 | 7162 | 0.030 |
Why?
|
| Tibia | 1 | 1996 | 70 | 0.030 |
Why?
|
| Fusarium | 1 | 1996 | 11 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 706 | 0.030 |
Why?
|
| Bacillus | 1 | 1996 | 34 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1996 | 90 | 0.030 |
Why?
|
| Health Services | 2 | 2006 | 71 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1997 | 308 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2024 | 0.030 |
Why?
|
| Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1584 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 669 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1996 | 190 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8111 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 822 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 290 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2013 | 48 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 66 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 2227 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 1140 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 404 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 1237 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1419 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5047 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 861 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 254 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 66 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 409 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 238 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 378 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2010 | 124 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 254 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 192 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2055 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1590 | 0.020 |
Why?
|
| Family Health | 1 | 2006 | 259 | 0.020 |
Why?
|
| Michigan | 1 | 2005 | 39 | 0.020 |
Why?
|
| Japan | 1 | 2005 | 132 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1394 | 0.010 |
Why?
|